Targeted Strategies for Today's Evolving Markets

MissionIR Blog

BioSpecifics Technologies Corp. (BSTC) to Present at the ROTH Capital Partners 24th Annual Conference

BioSpecifics Technologies is a biopharm company that has developed injectable collagenase for 12 clinical indications. BioSpecifics and partner Auxilium Pharmaceuticals, Inc. have developed injectable collagenase XIAFLEX®, which is approved in the U.S. for the treatment of Dupuytren’s contracture in adults with a palpable cord in the palm. Auxilium is also developing XIAFLEX to treat Peyronie’s disease as well as for frozen shoulder (adhesive capsulitis) and cellulite. For more information visit the company’s Web site at www.biospecifics.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below:

This year's annual ROTH Conference will take place at The Ritz Carlton located in Laguna Niguel, on March 17-12, 2013. Bringing together executives from more than 400 growth companies, the ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com.
This entry was posted in ROTH Capital Partners Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *